Significans iter MAPK/ERK

Significans iter MAPK/ERK vel significans iter Ras-Raf-MEK-ERK est signum transductus intra cellulam quocum factor crementis epidermalis (abbreviatura Anglica EGF) cyclo cellulari communicat per seriem enzymorum, inter quae greges phosphati pessuli (cum phosphatu aperti; sine phosphatu clausi) valent. Machinatio itineris etiam ambitum retroactionis negativae includit^[1].

Inhibitores illorum ut Raf inhibitores et MEK inhibitores tractationi cancrum inserviant^[2]^[3]^[4].

Partes MAPK/ERK itineris

Iter ERK ex subsystematibus SOS, Ras et MAPK compositum est.

Subsystema complexus SOS

Initio EGFR (receptorium factoris crementis epidermalis)^[5] signum recipit, tum dimerum duorum receptoriorum formans, phosphorum accipiens, deinde cum duobus proteinis adaptoribus (SHC1, Grb2) proteinoque crepidine (FRS2) connectens denique per SOS1 (abbreviatura Anglica: Son of Sevens) signum ad subsystema Ras transmittit.

Proteinum 14-3-3 cum SOS1 coniungere, eo modo iter inhibere, potest.

Subsystema Ras

Proteina RAS sunt GTPases parvae.

Subsystema MAPK

MAPK est abbreviatura mitogeno activatae proteini kinasis. Kinasis est subtypus enzymorum, qui phosphatum transfert, dehinc proteini kinasi phosphatum ad proteina transfert et praecipue ad proteinorum acida aminica serini, threonini, tyrosini, histidini. Eisdem kinasibus mitogeno activatae enim proteini kinases imprimis acidis aminicis serini et threonini phosphatum attribuitur. Mammaliis plus quam duodecim MAPK sunt.

Morbi et MAPK/ERK (exempla)

Incrementum numeri cellularum adenocarcinomatis pulmonum cum MAPK/ERK coniunctum videtur^[6].

Notae

↑ Lake D, Corrêa SA, Müller J (2016). "Negative feedback regulation of the ERK1/2 MAPK pathway". Cell Mol Life Sci 73 (23): 4397-413
↑ Hilger RA, Scheulen ME, Strumberg D (dec 2002). "The Ras-Raf-MEK-ERK pathway in the treatment of cancer" (PDF). Onkologie 25 (6): 511–8 .
↑ Sebolt-Leopold JS (iun 2008). "Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway". Clin. Cancer Res. 14 (12): 3651–6 .
↑ Hoshino R, Chatani Y, Yamori T, et al. (ian 1999). "Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors". Oncogene 18 (3): 813–22 .
↑ Oda K, Matsuoka Y, Funahashi A, Kitano H (2005). "A comprehensive pathway map of epidermal growth factor receptor signaling". Mol Syst Biol 1: 2005.0010
↑ Stutvoet T. S., Kol A., et al. (Sep 2019). "MAPK Pathway Activity Plays a Key Role in PD-L1 Expression of Lung Adenocarcinoma Cells". The journal of pathology 249 (1): 52-64

Nexus interni

[1] Lake D, Corrêa SA, Müller J (2016). "Negative feedback regulation of the ERK1/2 MAPK pathway". Cell Mol Life Sci 73 (23): 4397-413

[2] Hilger RA, Scheulen ME, Strumberg D (dec 2002). "The Ras-Raf-MEK-ERK pathway in the treatment of cancer" (PDF). Onkologie 25 (6): 511–8 .

[3] Sebolt-Leopold JS (iun 2008). "Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway". Clin. Cancer Res. 14 (12): 3651–6 .

[4] Hoshino R, Chatani Y, Yamori T, et al. (ian 1999). "Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors". Oncogene 18 (3): 813–22 .

[5] Oda K, Matsuoka Y, Funahashi A, Kitano H (2005). "A comprehensive pathway map of epidermal growth factor receptor signaling". Mol Syst Biol 1: 2005.0010

[6] Stutvoet T. S., Kol A., et al. (Sep 2019). "MAPK Pathway Activity Plays a Key Role in PD-L1 Expression of Lung Adenocarcinoma Cells". The journal of pathology 249 (1): 52-64

[1]

[2]

[3]

[4]

[5]

[6]